Indeed, the history of anti-obesity medications has been marked by several failures due to serious adverse events, such as suicidality, observed only after their usage had become extensive 221,234 a well-known example being the one that led to the withdrawal of the endocannabinoid inverse agonist, rimonabant 235
M., Sharp, J
While studies have primarily only looked at SGLT-2 in kidney transplant patients, we can hypothesize comparable results among liver transplant recipients
Some clinicians are exploring microdosing GLP-1 for autoimmune conditions specifically, using lower-than-standard doses to capture anti-inflammatory benefits while minimizing side effects and metabolic disruption
The people in the 240 milligram arm who remained on treatment lost, on average, 15% of their body weight
What are the opportunities and risks for investors